Introduction: The potential complications of antiepileptic drugs render them risky and associated with numerous morbidities for long-term therapy. Therefore, it is essential to balance therapy discontinuation against risks of epilepsy recurrence. However, the risk factors predicting recurrence are yet to be identified. The present study was conducted in order to determine the rate of recurrence after gradual therapy discontinuation as well as its influential factors in epileptic patients under medical therapy who were seizure-free for a period of 2 years.

Method And Materials: This is a descriptive cross-sectional study on epileptic patients who referred to the specialized neurology clinic of Kermanshah University of Medical Sciences from 1994 to 2010. The data were extracted from patients' medical records and analyzed.

Findings: A total of 391 patients were evaluated. In our study, 51.2% of patients experienced recurrence of seizure at the end of the 2-year follow-up. Recurrence occurred most frequently during medication tapering (51%). While the largest number of patients were aged under 12 years (178 patients; 45%), the rate of recurrence was greatest for patients aged 20-40 years (43 patients; 66.2%).

Discussion And Conclusion: As our findings suggest, type of epilepsy, multidrug therapy, abnormal electroencephalography before discontinuation, and abnormal brain computed tomography scan are factors that influence the risk of recurrence after therapy discontinuation. It is essential for the physician to take these factors into account and weigh the risk of recurrence against the benefits of therapy discontinuation.

Download full-text PDF

Source
http://dx.doi.org/10.3109/00207454.2012.694936DOI Listing

Publication Analysis

Top Keywords

therapy discontinuation
20
rate recurrence
12
epileptic patients
12
recurrence
9
patients
9
therapy
8
patients aged
8
risk recurrence
8
discontinuation
6
evaluating rate
4

Similar Publications

A 71-year-old man presented for a routine physical examination with multiple comorbidities, including severe panvascular disease and valvulopathy, requiring anticoagulation therapy. He had a history of chronic hemolytic anemia and had been taking oral ferrous sulfate for two years. Upper gastrointestinal endoscopy (UGE) was performed, as part of the study of the persist anemia, revealing an extensive nodular area with multiple brownish deposits and spontaneous hemorrhage.

View Article and Find Full Text PDF

Background: The development of immunotherapy has led to a paradigm shift in the treatment of malignant tumors. Immune checkpoint inhibitors (ICIs) function by blocking the receptors and ligands of T cells from binding one another, empowering them to target and attack cancer cells. ICIs along with other immunotherapy treatments, have seen a significant increase in usage in recent years.

View Article and Find Full Text PDF

Background: Although systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life phase is challenging. The aim of this study was to investigate the frequency and type of systemic therapy received by melanoma patients in their end-of-life phase.

View Article and Find Full Text PDF

Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukaemia: A Case Report and Literature Review.

Respirol Case Rep

March 2025

Pulmonary Hypertension Clinic, Division of Cardiology and Advanced Heart Failure Community Health Network Indianapolis Indiana USA.

Dasatinib, a second-generation tyrosine kinase inhibitor used for treating chronic myeloid leukaemia (CML), is associated with rare but significant adverse effects, including pulmonary arterial hypertension. This condition is thought to result from endothelial dysfunction and vascular remodelling linked to Src kinase inhibition. Symptoms such as progressive dyspnoea and fatigue may appear months or years after starting therapy, emphasising the need for long-term vigilance.

View Article and Find Full Text PDF

Background And Purpose: Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!